Human multipotent adult progenitor cells are nonimmunogenic and exert potent immunomodulatory effects on alloreactive T-cell responses

Cell Transplantation

Volumn 22, Issue 10, 2013, Pages 1915-1928

  Jacobs, Sandra A ^a,b   Pinxteren, Jef ^c   Roobrouck, Valerie D ^a   Luyckx, Ariane ^a   van't Hof, Wouter ^d   Deans, Robert ^d   Verfaillie, Catherine M ^a   Waer, Mark ^a   Billiau, An D ^a   Van Gool, Stefaan W ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ReGenesys   (Belgium)

^d ATHERSYS INC   (United States)

Author keywords

Allogeneic T cells; Cellular stem cell therapy; Human multipotent adult progenitor cells (hMAPCs); Immunomodulation

Indexed keywords

ALLOANTIGEN; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT STEM CELL; ALLOIMMUNITY; ARTICLE; BRAIN ISCHEMIA; CELL ISOLATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DNA SYNTHESIS; ENZYME ACTIVITY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LIQUID SCINTILLATION COUNTING; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; MULTIPOTENT STEM CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SECONDARY IMMUNE RESPONSE; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADULT; ALLOGRAFTS; BONE MARROW CELLS; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CYTOKINES; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; MULTIPOTENT STEM CELLS; T-LYMPHOCYTES;

EID: 84884682563     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X657369     Document Type: Article

References (31)

1. Aggarwal, S.; Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822; 2005.
2. Boozer, S.; Lehman, N.; Lakshmipathy, U.; Love, B.; Raber, A.; Maitra, A.; Deans, R.; Rao, M. S.; Ting, A. E. Global characterization and genomic stability of human MultiStem, a multipotent adult progenitor cell. J. Stem Cells 4:17-28; 2009.
3. Daubener, W.; Wanagat, N.; Pilz, K.; Seghrouchni, S.; Fischer, H. G.; Hadding, U. A new, simple, bioassay for human IFN-H. J. Immunol. Methods 168:39-47; 1994.
4. Di Nicola, M.; Carlo-Stella, C.; Magni, M.; Milanesi, M.; Longoni, P. D.; Matteucci, P.; Grisanti, S.; Gianni, A. M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843; 2002.
5. Han, K. H.; Ro, H.; Hong, J. H.; Lee, E. M.; Cho, B.; Yeom, H. J.; Kim, M. G.; Oh, K. H.; Ahn, C.; Yang, J. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl. Immunol. 25:7-15; 2011.
6. Highfill, S. L.; Kelly, R. M.; O'shaughnessy, M. J.; Zhou, Q.; Xia, L.; Panoskaltsis-Mortari, A.; Taylor, P. A.; Tolar, J.; Blazar, B. R. Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 114:693-701; 2009.
7. Jiang, Y.; Jahagirdar, B. N.; Reinhardt, R. L.; Schwartz, R. E.; Keene, C. D.; Ortiz-Gonzalez, X. R.; Reyes, M.; Lenvik, T.; Lund, T.; Blackstad, M.; Du, J.; Aldrich, S.; Lisberg, A.; Low, W. C.; Largaespada, D. A.; Verfaillie, C. M. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49; 2002.
8. Koc, O. N.; Gerson, S. L.; Cooper, B. W.; Dyhouse, S. M.; Haynesworth, S. E.; Caplan, A. I.; Lazarus, H. M. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18:307-316; 2000.
9. Kovacsovics-Bankowski, M.; Streeter, P. R.; Mauch, K. A.; Frey, M. R.; Raber, A.; Van't Hof, W.; Deans, R.; Maziarz, R. T. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell. Immunol. 255:55-60; 2009.
10. Kuo, T. K.; Ho, J. H.; Lee, O. K. Mesenchymal stem cell therapy for nonmusculoskeletal diseases: Emerging applications. Cell Transplant. 18:1013-1028; 2009.
11. Lazarus, H. M.; Koc, O. N.; Devine, S. M.; Curtin, P.; Maziarz, R. T.; Holland, H. K.; Shpall, E. J.; McCarthy, P.; Atkinson, K.; Cooper, B. W.; Gerson, S. L.; Laughlin, M. J.; Loberiza, Jr., F. R.; Moseley, A. B.; Bacigalupo, A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11:389-398; 2005.
12. Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M. E.; Remberger, M.; Dini, G.; Egeler, R. M.; Bacigalupo, A.; Fibbe, W.; Ringden, O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371:1579-1586; 2008.
13. Le Blanc, K.; Rasmusson, I.; Gotherstrom, C.; Seidel, C.; Sundberg, B.; Sundin, M.; Rosendahl, K.; Tammik, C.; Ringden, O. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand. J. Immunol. 60:307-315; 2004.
14. Le Blanc, K.; Rasmusson, I.; Sundberg, B.; Gotherstrom, C.; Hassan, M.; Uzunel, M.; Ringden, O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441; 2004.
15. Le Blanc, K.; Ringden, O. Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262:509-525; 2007.
16. Le Blanc, K.; Samuelsson, H.; Gustafsson, B.; Remberger, M.; Sundberg, B.; Arvidson, J.; Ljungman, P.; Lonnies, H.; Nava, S.; Ringden, O. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21:1733-1738; 2007.
17. Luyckx, A.; De Somer, L.; Jacobs, S.; Rutgeerts, O.; Lenaerts, C.; Roobrouck, V. D.; Verfaillie, C. M.; Waer, M.; Van Gool, S. W.; Billiau, A. D. Oct4-negative multipotent adult progenitor cells and mesenchymal stem cells as regulators of T-cell alloreactivity in mice. Immunol. Lett. 137:78-81; 2011.
18. Luyckx, A.; De Somer, L.; Rutgeerts, O.; Waer, M.; Verfaillie, C. M.; Van Gool, S.; Billiau, A. Mouse MAPCmediated immunomodulation: Cell-line dependent variation. Exp. Hematol. 38:1-2; 2010.
19. Meisel, R.; Brockers, S.; Heseler, K.; Degistirici, O.; Bulle, H.; Woite, C.; Stulhsatz, S.; Schwippert, W.; Jager, M.; Sorg, R.; Henschler, R.; Seissler, J.; Dilloo, D.; Daubener, W. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25: 648-654; 2011.
20. Meisel, R.; Zibert, A.; Laryea, M.; Gobel, U.; Daubener, W.; Dilloo, D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 103:4619-4621; 2004.
21. Nauta, A. J.; Fibbe, W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506; 2007.
22. Plumas, J.; Chaperot, L.; Richard, M. J.; Molens, J. P.; Bensa, J. C.; Favrot, M. C. Mesenchymal stem cells induce apoptosis of activated T-cells. Leukemia 19:1597-1604; 2005.
23. Rasmusson, I.; Ringden, O.; Sundberg, B.; Le Blanc, K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305:33-41; 2005.
24. Ren, G.; Su, J.; Zhang, L.; Zhao, X.; Ling, W.; L'huillie, A.; Zhang, J.; Lu, Y.; Roberts, A. I.; Ji, W.; Zhang, H.; Rabson, A. B.; Shi, Y. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27:1954-1962; 2009.
25. Roobrouck, V. D.; Clavel Claver, C.; Jacobs, S. A.; Ulloa-Montoya, F.; Crippa, S.; Sohni, A.; Roberts, S. J.; Luyten, F. P.; Van Gool, S. W.; Sampaolesi, M.; Delforge, M.; Luttun, A.; Verfaillie, C. M. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 29:871-882; 2011.
26. Tolar, J.; O'shaughnessy, M. J.; Panoskaltsis-Mortari, A.; McElmurry, R. T.; Bell, S.; Riddle, M.; Mclvor, R. S.; Yant, S. R.; Kay, M. A.; Krause, D.; Verfaillie, C. M.; Blazar, B. R. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood 107:4182-4188; 2006.
27. Torrente, Y.; Polli, E. Mesenchymal stem cell transplantation for neurodegenerative diseases. Cell Transplant. 17:1103-1113; 2008.
28. Tse, W. T.; Pendleton, J. D.; Beyer, W. M.; Egalka, M. C.; Guinan, E. C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 75:389-397; 2003.
29. Uccelli, A.; Moretta, L.; Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8:726-736; 2008.
30. Ulloa-Montoya, F.; Kidder, B. L.; Pauwelyn, K. A.; Chase, L. G.; Luttun, A.; Crabbe, A.; Geraerts, M.; Sharov, A. A.; Piao, Y.; Ko, M. S.; Hu, W. S.; Verfaillie, C. M. Comparative transcriptome analysis of embryonic and adult stem cells with extended and limited differentiation capacity. Genome Biol. 8:R163; 2007.
31. Yagi, H.; Soto-Gutierrez, A.; Parekkadan, B.; Kitagawa, Y.; Tompkins, R. G.; Kobayashi, N.; Yarmush, M. L. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 19:667-679; 2010.